-
r37980778c78--42d6c4c7018d7a39ebae4da110bb5f38
Performance of our system in finding the association between genomic anomaly and drug responses in PharmGKB dataset. -
Subgroup analysis according to the route of administration (injectable vs. or...
Subgroup analysis according to the route of administration (injectable vs. oral) of eligible disease modifying therapies for the treatment of relapsing-remitting multiple... -
Model parameters.
aSpecified with reference to Cook [30] and Waage et al. [36] using distributions defined in Biosecurity Australia [31]; b Derived from Sapoukhina et al. [37]; c ABS [6], Note... -
Subgroup analysis by cancer type, target, generation, animal model, and publi...
Subgroup analysis by cancer type, target, generation, animal model, and publication year. -
r37980778c78--d2b01fbad6db94bc8d20487a017d0cb8
Barriers (b) and facilitators (f) for GPs to refer patients with neck pain to the manual therapist. -
Baseline characteristics of patients with AF according to preoperative usage ...
Baseline characteristics of patients with AF according to preoperative usage of aspirin vs VKA. -
r37980778c78--b543e5225231fdcc0e7ce627e097eb5a
Severity of subarachnoid haemorrhage, incidence of vasospasm and outcome data. -
Potential risk factors and outcomes of an amputation in longstanding therapy ...
Potential risk factors and outcomes of an amputation in longstanding therapy resistant CRPS-I. -
Items in the questionnaire corresponding to different components and topics.
For each item, both the full question and its abbreviated item name are shown. -
Results of the 2 regression analyses with change in worst pain in the past we...
Model 1 without controlling for education, model 2 with controlling for education. -
Beyond disease-progression: Clinical outcomes after <i>EGFR</i>-TKIs in a coh...
PurposeTreatment and clinical-outcomes were described in a sub-cohort of non-small-cell lung cancer (NSCLC) patients with disease-progression (PD) after epidermal growth factor... -
r37980778c78--e77c9b2032a2d01deb19976bd4b24c7d
Probability of escalation to the next higher dose for each underlying true DLT rate.